Skip to main content ( press enter )

Surgical management of melanoma at all disease stages

Active research protocols are reviewed regularly, and our aim is to maximise the number of patients on current studies. In addition to major studies, both investigator led and other multicentre studies, are undertaken by junior trainees using Peter Mac’s extensive patient numbers and databases

Research projects 

Major studies

  • Margins of Excision Trial  MELMARTA Phase III, multicentre, multinational randomised control trial investigating 1cm (about 0.39 in) v 2cm (about 0.79 in) wide excision margins for primary cutaneous melanoma. Peter Mac and its investigators are the national and international leads for this study 

  • Multicentre Selective Lymphadenectomy Trial (MSLT-II): A Phase III Multicentre Randomised Trial of Sentinel Lymphadenectomy and complete Lymph Node Dissection versus Sentinel Lymphadenectomy Alone in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node. Study complete  with ongoing follow up. 

  • Melanoma Research Victoria (Formerly Melbourne Melanoma Project) - prospective demographic and genomic database.

  • Use of Glubran2 to reduce seroma formation following inguinal lymphadenectomy - a randomised phase II trial. 

  • A prospective cohort study of patients with stage 3 and 4 melanomas at Peter MacCallum Cancer Centre. 

Clinical research 

  • Surgical Margins and prognosis in advanced melanoma of the head and neck; a retrospective study. 

  • Growth dynamics of malignant melanoma. 

  • Review of Rose-Bengal in cutaneous melanoma metastasis - The Peter Mac Experience. 

  • Resected macroscopic nodal metastatic malignant melanoma. 

  • Characteristics and prognosis of cutaneous SCC (Squamous Cell Carcinomas) in patients with CLL (Chronic Lymphocytic Leukaemia). 

  • Anal Melanoma; a review of the Peter MacCallum Cancer Case Series. 

  • A multicentre, retrospective review of treatment patterns and outcomes for patients with locally advanced or metastatic basal cell carcinoma in Australia. 

  • The staging of patients presenting with newly diagnosed stage III melanoma. 

  • Management and outcome of patients with high risk (>4mm) T4 melanomas. 

  • The Outcome of Patients with Popliteal and Epitochlear Sentinel Nodes. 

  • Studying the effect of mutation type on the immune phenotype of melanoma – a pilot study. 

  • Prognostic factors for early local recurrence of cutaneous melanoma. 

  • A prospective cohort study of patients with stage 3 and 4 melanomas at Peter MacCallum Cancer Centre. 

  • Identifying the prospective significance of immune infiltrate in primary melanoma. 

  • Ongoing Quality Assurance Review

Contact 

Professor Michael A Henderson 

  • Email: This email address is being protected from spambots. You need JavaScript enabled to view it. 

Further info 

Multidisciplinary Team Surgeon Lead 

  • Professor Michael A Henderson 

Tumour Stream Surgeons 

  • Professor Michael Henderson 

  • Mr David Speakman 

  • Mr John Spillane 

  • Associate Professor David Gyorki 

  • Dr Hayden Snow 

  • Dr Robert Tasevski 

  • Dr Michael Findlay 

  • Associate Professor Chris McCormack 

  • Dr Michelle Goh 

Back to top